Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Junko Tanizaki, MD, PhD"'
Autor:
Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100590- (2023)
Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these cura
Externí odkaz:
https://doaj.org/article/3f386ee3f72d427a96a00d99cb19bacc
Autor:
Hiroaki Kanemura, MD, MPH, Hidetoshi Hayashi, MD, PhD, Shuta Tomida, PhD, Junko Tanizaki, MD, PhD, Shinichiro Suzuki, MD, PhD, Yusuke Kawanaka, MD, Asuka Tsuya, MD, Yasushi Fukuda, MD, Hiroyasu Kaneda, MD, PhD, Keita Kudo, MD, Takayuki Takahama, MD, PhD, Ryosuke Imai, MD, Koji Haratani, MD, PhD, Yasutaka Chiba, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100373- (2022)
Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients. M
Externí odkaz:
https://doaj.org/article/dbb20eead9094769a8713112200e34c2
Autor:
Daichi Fujimoto, MD, Satoru Miura, MD, PhD, Kenichi Yoshimura, MD, PhD, Kazushige Wakuda, MD, Yuko Oya, MD, Koji Haratani, MD, PhD, Shoichi Itoh, MD, Takehiro Uemura, MD, PhD, Ryotaro Morinaga, MD, PhD, Takayuki Takahama, MD, PhD, Kazuhisa Nakashima, MD, Motoko Tachihara, MD, PhD, Go Saito, MD, Junko Tanizaki, MD, PhD, Kohei Otsubo, MD, PhD, Satoshi Ikeda, MD, Hirotaka Matsumoto, MD, Satoshi Hara, MD, Akito Hata, MD, Takeshi Masuda, MD, PhD, Nobuyuki Yamamoto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100265- (2022)
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor perform
Externí odkaz:
https://doaj.org/article/334d6452dbd74ae68a67e6425d4802e8
Autor:
Kiichiro Ninomiya, MD, PhD, Shunsuke Teraoka, MD, Yoshitaka Zenke, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Yukiko Nakamura, MD, Yusuke Okuma, MD, PhD, Akihiro Tamiya, MD, Kaname Nosaki, MD, Masahiro Morise, MD, PhD, Keiju Aokage, MD, Yuko Oya, MD, Toshiyuki Kozuki, MD, PhD, Tomohiro Sakamoto, MD, PhD, Kentaro Tanaka, MD, PhD, Hisashi Tanaka, MD, PhD, Junko Tanizaki, MD, PhD, Satoru Miura, MD, PhD, Hideaki Mizutani, MD, Eisaku Miyauchi, MD, PhD, Ou Yamaguchi, MD, PhD, Noriyuki Ebi, MD, Yasushi Goto, MD, PhD, Takaaki Sasaki, MD, PhD, Haruko Daga, MD, PhD, Satoshi Morita, PhD, Takeharu Yamanaka, PhD, Shinsuke Amano, BCom, Kazuo Hasegawa, BFA, Chiyo K. Imamura, PhD, Kenichi Suzuki, PhD, Kazuko Nakajima, PhD, Hitomi Nishimoto, MN, Satoshi Oizumi, MD, PhD, Toyoaki Hida, MD, PhD, Katsuyuki Hotta, MD, PHD, MPH, Yuichi Takiguchi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100107- (2021)
Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee. The purp
Externí odkaz:
https://doaj.org/article/5ceda8a606294ebc9bef7784fdc89eeb